Unveiling Immune Infiltration Characterizing Genes in Hypertrophic Cardiomyopathy Through Transcriptomics and Bioinformatics
DOI: https://doi.org/10.2147/jir.s454446
IF: 4.5
2024-05-17
Journal of Inflammation Research
Abstract:Jianmin Gong, 1, 2, &ast Bo Shi, 1, 3, &ast Ping Yang, 1 Adeel Khan, 4 Tao Xiong, 2 Zhiyang Li 1 1 Department of Clinical Laboratory, Nanjing Drum Tower Hospital, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, 210000, People's Republic of China; 2 College of Life Science, Yangtze University, Jingzhou, 434025, People's Republic of China; 3 Department of Clinical Laboratory, Nanjing Jiangning Hospital of Chinese Medicine (CM), Nanjing, 211100, People's Republic of China; 4 Department of Biotechnology, University of Science and Technology Bannu, Bannu, 28100, Islamic Republic of Pakistan &astThese authors contributed equally to this work Correspondence: Tao Xiong, College of Life Science, Yangtze University, Jingzhou, 434025, People's Republic of China, Tel +8613872387410, Email Zhiyang Li, Department of Clinical Laboratory, Nanjing Drum Tower Hospital, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, 210008, People's Republic of China, Tel +8618951703765, Email Background: Hypertrophic cardiomyopathy (HCM) is a dominantly inherited disease associated with sudden immune cell associations that remain unclear. The aim of this study was to comprehensively screen candidate markers associated with HCM and immune cells and explore potential pathogenic pathways. Methods: First, download the GSE32453 dataset to identify differentially expressed genes (DEGs) and perform Gene Ontology and pathway enrichment analysis using DAVID and GSEA. Next, construct protein-protein interaction (PPI) networks using String and Cytoscape to identify hub genes. Afterward, use CIBERSORT to determine the proportion of immune cells attributed to key genes in HCM and conduct ROC analysis based on the external dataset GSE36961 to evaluate their diagnostic value. Finally, validate the expression of key genes in the hypertrophic cardiomyocyte model through qRT-PCR using data from the HPA database. Results: Comprehensive analysis revealed that there were 254 upregulated genes and 181 downregulated genes in HCM. The enrichment study underscored pathways of inflammatory signaling, including MAPK and PI3K-Akt pathways. Pathways abundant in genes associated with HCM encompassed myocardial contraction and NADH dehydrogenase activity. Additionally, the analysis of immune infiltration revealed a notable increase in macrophages, NK cells, and monocytes in the HCM group, showing statistically significant variances in CD4 memory resting T cell infiltration when compared to the healthy control group. Within the validation dataset GSE36961, the Area Under the Curve (AUC) scores for eight crucial genes (FOS, CD86, CD68, BDNF, PIK3R1, PLEK, RAC2, CCL2) each exceeded 0.8. The HPA database revealed the positioning traits and paths of these eight crucial genes in smooth muscle cells, myocardial cells, and fibroblasts. The outcomes of the qRT-PCR were aligned with the sequencing findings. Conclusion: Bioinformatics analysis unveiled pivotal genes, pathways, and immune involvement, illuminating the molecular underpinnings of HCM. These findings suggest promising therapeutic targets for clinical applications. Keywords: hypertrophic cardiomyopathy, bioinformatic, immune cells infiltration, biomarker Hypertrophic cardiomyopathy (HCM) is a heterogenic genetic disease most commonly caused by sarcomeric mutations that lead to left ventricular hypertrophy, fibrosis, hypercontractility and reduced compliance. 1 The intricate nature of hypertrophic cardiomyopathy involves a combination of diastolic dysfunction, myocardial ischaemia, and outflow tract obstruction and arrhythmias caused by the displacement of the mitral valve in the front. From a clinical standpoint, the symptomatology exhibits a wide range, encompassing no discernible symptoms as well as palpitations, dyspnoea, diminished exercise capacity, chest discomfort, syncope, and even abrupt demise. 2 Epidemiological studies indicate that at least 1 in every 500 individuals is affected by hypertrophic cardiomyopathy, while 1 in every 200 individuals is either affected by it or has a genetic predisposition. 3 Despite functional and genome-wide association studies (GWAS) suggesting an association between the FHOD3 gene and myocardial hypertrophy, no pathogenic variants directly related to hypertrophic cardiomyopathy have been identified. 4 While significant progress has been made in the diagnosis through the use of echocardiography, clinical diagnosis still faces several challenges, including the diversity of clinical manifestations, uncertainty in imaging exa -Abstract Truncated-
immunology